XuanZhuBio-B (02575) announced that on April 9, 2026, the Group, as the licensor, entered into a licensing and supply agreement with Boston Oncology CGT Holding Co. Limited, the licensee, concerning piroxiclib (brand name: XuanYueNing®) and diroac (brand name: XuanFeiNing®). Piroxiclib is a CDK2/4/6 inhibitor independently developed by the Group for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Diroac is a new-generation anaplastic lymphoma kinase (ALK) inhibitor, also independently developed by the Group, for treating ALK-positive advanced non-small cell lung cancer.

Under the licensing and supply agreement, the licensor has granted the licensee an exclusive license to develop, register, and commercialize both piroxiclib and diroac within the authorized territory, which encompasses 21 countries and regions in the Middle East and North Africa. The licensor will receive an upfront payment and potential future regulatory and commercial milestone payments that could cumulatively exceed $100 million, in addition to fixed-percentage royalty fees based on total sales within the authorized region. The licensor will supply the products to the licensee at an agreed-upon price to support the commercial development activities for the two drugs in the authorized territory.

The execution of this agreement represents a significant strategic move by the Group to expand its global market presence. By leveraging the licensee's established capabilities in drug registration, commercial promotion, and distribution networks across the Middle East and North Africa, the Group aims to accelerate the market entry and commercialization of piroxiclib and diroac in the region. This initiative is expected to enhance the global market coverage and brand influence of the Group's innovative pharmaceuticals. Furthermore, the fulfillment of this agreement is projected to generate sustained milestone and royalty revenues for the Group, optimizing its revenue structure and aligning with the overall interests of the Group and its shareholders.